Sirt1 Protects Endothelial Cells against LPS-Induced Barrier Dysfunction

Oxid Med Cell Longev. 2017:2017:4082102. doi: 10.1155/2017/4082102. Epub 2017 Oct 25.

Abstract

Sepsis is a threatening health problem and characterized by microvascular dysfunction. In this study, we verified that LPS caused the downregulation of Sirt1 and the hyperpermeability of endothelial cells. Inhibition of Sirt1 with ex527 or Sirt1 siRNA displayed a higher permeability, while activation of Sirt1 with SRT1720 reversed the LPS-induced hyperpermeability, formation of fiber stress, and disruption of VE-cadherin distribution. In pulmonary microvascular vein endothelial cells isolated from wild-type mice, Sirt1 was attenuated upon LPS, while Sirt1 was preserved in a receptor of advanced glycation end product-knockout mice. The RAGE antibody could also diminish the downregulation and ubiquitination of Sirt1 in LPS-exposed human umbilical vein endothelial cells. An LPS-induced decrease in Sirt1 activity was attenuated by the RAGE antibody and TLR4 inhibitor. In vivo study also demonstrated the attenuating role of Sirt1 and RAGE knockout in LPS-induced increases in dextran leakage of mesenteric venules. Furthermore, activation of Sirt1 prevented LPS-induced decreases in the activity and expression of superoxide dismutase 2, as well as the increases in NADPH oxidase 4 and reactive oxygen species, while inhibition of Sirt1 aggravated the SOD2 decline. It also demonstrated that Sirt1-deacetylated p53 is required for p53 inactivation, which reversed the downregulation of β-catenin caused by LPS.

MeSH terms

  • Animals
  • Down-Regulation / drug effects*
  • Heterocyclic Compounds, 4 or More Rings / pharmacology
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Lipopolysaccharides / toxicity*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • NADPH Oxidase 4 / metabolism
  • Permeability / drug effects*
  • RNA Interference
  • RNA, Small Interfering / metabolism
  • Reactive Oxygen Species / metabolism
  • Receptor for Advanced Glycation End Products / deficiency
  • Receptor for Advanced Glycation End Products / genetics
  • Receptor for Advanced Glycation End Products / immunology
  • Sirtuin 1 / antagonists & inhibitors
  • Sirtuin 1 / genetics
  • Sirtuin 1 / metabolism*
  • Superoxide Dismutase / metabolism
  • Toll-Like Receptor 4 / antagonists & inhibitors
  • Toll-Like Receptor 4 / metabolism
  • Tumor Suppressor Protein p53 / metabolism
  • beta Catenin / metabolism

Substances

  • Ager protein, mouse
  • Heterocyclic Compounds, 4 or More Rings
  • Lipopolysaccharides
  • RNA, Small Interfering
  • Reactive Oxygen Species
  • Receptor for Advanced Glycation End Products
  • SRT1720
  • Toll-Like Receptor 4
  • Tumor Suppressor Protein p53
  • beta Catenin
  • Superoxide Dismutase
  • NADPH Oxidase 4
  • Sirtuin 1